| abstract |
The 3,4-dihydrobenzoxazine compound of the present invention has the following formula [1] (wherein X is a nitrogen atom or CR 3 , R 1 is a hydrogen atom or a halogen atom, R 2 is the same selected from a halogen atom and a hydroxyl group) Or a C 1-6 alkoxy group which may be substituted with 1 to 5 different substituents, R 3 is a halogen atom, provided that when X is CR 3 , R 1 is a halogen atom. It is represented by These compounds are effective in the treatment of diseases involving vanilloid receptor type 1 (VR1) activity such as pain. |